The invention is directed to the use of (i) a first antigen corresponding to atarget antigen of interest, together with (ii) a second antigen, correspondingto a modified form of the target antigen, whose rate of intracellularproteolytic degradation is increased, enhanced or otherwise elevated relativeto the first antigen, in compositions and methods for inducing both humoraland cellular immunity in an individual. The ability to provide compositions,which are capable of inducing both host-protective antibody and cell-mediatedimmune responses, facilitates the generation of immunogenic compositionscapable of combating, inter alia, conditions that have long latency periodsand, therefore, benefit from the dual approach of prophylaxis and therapy inone delivery.
